Table 2.
Type of treatment for NAbs responders and non-responders on day 50.
| Day 50, n (%) | NAbs >50% (n = 114) (%) | NAbs <30% (n = 65) (%) |
|---|---|---|
| Off treatment | 23 (20.2) | 2 (3.1) |
| Belantamab mafodotin monotherapy | 0 | 2 (3.1) |
| Belantamab mafodotin combinations | 2 (1.7) | 5 (7.7) |
| Daratumumab monotherapy | 2 (1.7) | 6 (9.2) |
| Daratumumab + PI combinations | 5 (4.4) | 9 (13.9) |
| Anti-CD38 antibodies + IMID combinations | 14 (12.3) | 9 (13.9) |
| Other anti-CD38 combinations | 2 (1.8) | 1 (1.5) |
| IMID-based regimens | 11 (9.6) | 9 (13.9) |
| PI-based regimens | 6 (5.2) | 7 (10.7) |
| IMID and PI combinations | 25 (21.9) | 10 (15.3) |
| Lenalidomide maintenance | 23 (20.3) | 5 (7.7) |
| Cyclophosphamide | 1 (0.9) | – |
PI proteasome inhibitor, IMID immunomodulatory drug.